Menu UF Health Home Menu
 

Experimental Therapeutics

Program Description

The central goal of the Experimental Therapeutics Program is to promote the collaborative scientific interactions between basic scientists and clinicians involved in cancer research. The program seeks to bring together investigators with appropriate clinical, basic science, or technological expertise for the investigation of novel cellular, molecular, histopathologic and imaging endpoints in order to foster scientific research initiatives at the laboratory/clinic interface. The ultimate aim is to integrate the expertise of the bench researcher with the front-line clinician to foster clinical trial development.

Members of the Experimental Therapeutics Program conduct cancer research on a wide variety of topics/themes including:

  • Functional Genomics
  • Gene Expression Profiling
  • Cancer Cell Signaling
  • Tumor Microenvironments
  • Metastatic Cascade
  • Stem Cell Biology
  • Non-invasive Imaging and Biomarkers
  • Rodent and Large Animal Therapeutics
  • Gene and Immunotherapy
  • Vascular Directed Therapy
  • Combined Modalities and Drug Resistance
  • Dietary and Chemoprevention Strategies
  • Early Phase Clinical Trials

Research conducted in the Experimental Therapeutics Program endeavors to advance innovative ideas from basic science and clinical practice in order to develop future front-line detection techniques and state of the art therapies for cancer patients.

If you would like to become a member of the Cancer Center, please visit Membership Policy and Application to complete an application for membership.  If you have any questions about this process, please contact Matt Wooten at mwooten@ufl.edu or 352-273-8154.

Program Leader

Dietmar W. Siemann, PhD
(352) 265-0287
siemadw@ufl.edu


Research Funding Totals from Experimental Therapeutics Members

Fiscal Year 2013 Historical Research Base – Experimental Therapeutics

Direct Indirect Total
FY ’13 Grand Total for Historical Research Funding to Experimental Therapeutics Members $15,193,660 $2,075,686 $17,269,346
Allowable NIH – National Cancer Institute Only Research Funding $772,509 $242,630 $1,015,139
All Other National Institute of Health (NIH) Research Funding (May include NCI sub-projects) $3,936,219 $1,118,429 $5,054,648
Other Peer Reviewed Research Funding $2,213,789 $318,995 $2,532,784
Non-Peer Reviewed Research Funding $8,271,143 $395,632 $8,666,775

Fiscal Year 2012 Historical Research Base – Experimental Therapeutics

Direct Indirect Total
FY ’12 Grand Total for Historical Research Funding to Experimental Therapeutics Members $11,696,696 $2,225,848 $13,992,544
Allowable NIH – National Cancer Institute Only Research Funding $1,178,142 $403,442 $1,581,584
All Other National Institute of Health (NIH) Research Funding (May include NCI sub-projects) $3,368,226 $891,200 $4,259,426
Other Peer Reviewed Research Funding $1,657,475 $169,607 $1,827,082
Non-Peer Reviewed Research Funding $5,492,853 $761,598 $6,254,452

Members of Experimental Therapeutics

 Adhihetty, Peter  Frost, Susan  Lynch, James W.  Simpson, Nicholas E.
 Allegra, Carmen  Garrett, Timothy J.  Malyapa, Robert S.  Slopsema, Roelf L.
 Amdur, Robert J.  George, Thomas J.  Mamalui-Hunter, Maria  Sorg, Brian
 Antonelli, Patrick J.  Ghivizzani, Steven C.  Mann, Giselle D.  Srivastava, Arun
 Bacon, Nicholas J.  Goldberg, Eugene P.  Mareci, Thomas H.  Staal, Stephen
 Bae, Kyung-Mi  Gopalan, Priya K.  McFadden, Grant  Stechmiller, Bruce K.
 Baker, Henry V.  Herzog, Roland W.  Milner, Rowan J.  Steindler, Dennis A.
 Batich, Christopher D.  Hoppe, Bradford S.  Moldawer, Lyle L.  Su, Li-Ming
 Becker, Marie N.  Hsu, Jack W.  Moreb, Jan S.  Su, Zhong
 Behnke, Brad J.  Hughes, Steven J.  Moser, Patricia P.  Swarts, Steven G.
 Blackband, Stephen J.  Hurley, Robert W.  Muir, David F.  Terada, Naohiro
 Bolch, Wesley E.  Indelicato, Daniel J.  Muzyczka, Nicholas  Toskich, Beau B.
 Boston, Sarah E.  Jiang, Huabei  Nelson, David R.  Vidyasagar, Sadasivan
 Boulton, Michael E.  Judge, Andrew  Nichols, Romaine C.  Volpe, Carmine
 Bova, Frank J.  Kaye, Frederic J.  O’Dell, Walter G.  Wallace, Margaret (Peggy) R.
 Bubb, Michael R.  King, Michael A.  Oh, S. Paul  Wang, Kevin W.
 Bungert, Jorg  Klodell, Charles T.  Palta, Jatinder R.  Wingard, John R.
 Carney, Paul R.  Kow, Kelvin  Raisch, Kevin P.  Wirk, Baldeep “Mona”
 Caudle, Robert M.  Kubicek, Lyndsay N.  Reynolds, Brent  Wu, Lizi
 Cogle, Christopher R.  Lagmay, Joanne  Rice, Lori P.  Xie, Huikai
 Daaka, Yehia  Law, Brian K.  Riggs, Charles E.  Yachnis, Anthony
 Dahm, Philipp  Lee, Sang Yeob  Rinaldi, Carlos  Yeung, Anamaria R.
 Dai, Yao  Li, Jian  Ross, Heather H.  Zajac-Kaye, Maria
 Dang, Nam H.  Li, Ying  Samant, Sanjiv S.  Zhang, Mei
 Draganov, Peter  Li, Zuofeng  Sarosi, George A.  Zhang, Steven B.
 Dunn, William A.  Liao, Daiqing  Sayeski, Peter P.  Zhang, Zhenhuan
 Farmerie, William G.  Lightsey, Judith L.  Segal, Mark S.  Zhou, Lei
 Fletcher, Bradley S.  Lu, Jianrong  Siemann, Dietmar W.  Zlotecki, Robert A.